After Anthropic rang the bell, which publicly traded companies were rewritten by AI large models?

CN
1 hour ago

Original|Odaily Planet Daily(@OdailyChina)

Author|Wenser(@wenser 2010 )179516771338837.jpg

On the evening of November 19, the “largest IPO in history” Anthropic officially concluded its listing, with a fully diluted market value reaching as high as $1.8 trillion at one point, placing it among the “Top 10 highest valued companies in the world.”

Before the listing bell rang, Anthropic co-founder Dario discussed topics such as the evolution of AI model capabilities, safety slowdowns, and investments in computing power and cash. He also mentioned, “Collaboration between AI and humans is expected to compress a century of scientific and medical progress into 10 years,” and pledged in the “Founders’ Public Letter” that Claude would never incorporate advertising.

Overall, Dario painted a macro vision of “the future of humanity hinges on AI;” however, behind this narrative, he also laid the groundwork for several sectors that might be under pressure. Of course, as AI rapidly advances, technology giants and healthcare leaders are also evolving quickly in their own ways. With AI as a powerful tool, its future direction remains uncertain.

The Landscape Behind Anthropic's IPO: Safety, Healthcare, and Chips

The reason for the rapid and urgent progress of Anthropic’s IPO is that, although previous financing has reached round H, the company still faces rising computing costs and the necessary challenges of cybersecurity defense. These two areas are also the two major sectors that will be directly impacted after its IPO. Healthcare is one of Dario’s main targets of “facing challenges” and “painting a grand picture.” Let’s take a closer look one by one.

Impact One: Positive for Cybersecurity Stocks, Negative for Software Stocks

First, regarding the cybersecurity sector, although we have entered a grand era of “national AI security offense and defense” with the development of large AI models, this cannot be viewed as entirely negative for cybersecurity companies. On one hand, this means “increased business;” on the other hand, large AI models are also helping cybersecurity firms efficiently screen vulnerabilities and promptly fix bugs.

For Nasdaq-listed company Palo Alto Networks (PANW), this is an industrial advantage. Dario has repeatedly flagged cyberattacks as the most realistic dual-use risk, and the “Founders’ Public Letter” mentioned the Project Glasswing defense initiative launched in April this year, with PANW as one of the first core partners. Public information disclosure indicates that in May, PANW utilized Anthropic’s Claude Mythos, Claude Opus 4.7, and OpenAI’s GPT-5.5-Cyber, scanning over 130 products in about a month and identifying 75 valid vulnerabilities, far exceeding the usual monthly disclosure rate of 5 to 10. Internal testing showed that the success rate of the advanced models combining multiple minor risks into usable attack paths exceeded 70%, but also accompanied by about a 30% false positive rate, requiring the security team to invest significant engineering efforts to build dedicated scanning safeguards. Founded in 2011, another security company, CrowdStrike (CRWD), experienced a similar situation with a stock price increase of up to 49.79% in the past six months; although the performance of such companies is indeed the main reason for the stock price rise, the development of large AI models has indeed played a boosting role to some extent.

In sharp contrast are software stocks.

In the enterprise SaaS software sector, Salesforce (NYSE: CRM) is noteworthy. Despite the fact that the case study released on Anthropic’s IPO website shows that its engineering team increased effective output per person by 151% and reduced online incident rates by 5% with the assistance of the Claude model; and although both have made product-level cooperation configurations, with Salesforce holding less than 1% of Anthropic's equity, Anthropic still poses a certain threat. Salesforce’s stock has dropped as much as 24.39% in the past month.

179516772013481.jpg

The capital market continues to weigh the advantages of cost reduction and efficiency versus the discount on positions. A similar timing mismatch also occurred for IT consulting and systems integration giant Accenture (ACN). Although Anthropic's prospectus and roadshow video listed Accenture as an important customer and integration partner, and Accenture CEO Julie Sweet revealed that the large model integration and compliance needs of major government and enterprise clients would bring a new wave of systems integration and data governance orders, whether these orders can be sustainably effective long-term remains uncertain.

Impact Two: Healthcare, National Defense Security, and Computing Power Chips

At the bell-ringing platform, Dario painted a grand vision but also left an escape route for Anthropic. His original quote suggested that “large AI models are expected to compress a century of medical progress into ten years,” which is merely a long-term vision, and the current stage is still in the early results phase, with medical experiments and clinical trials still requiring some time.

As a specific case, the healthcare giants are most prominent.

When it comes to specific pharmaceutical companies, Eli Lilly (LLY) has made more solid progress. According to the “Eli Lilly Case Study” published by Anthropic, starting from 2024 with access to Claude, the company became one of the first large pharmaceutical firms to offer Claude Enterprise to over 50,000 employees, with full-time employee engagement exceeding 85% across five major functions: legal compliance, technology, finance, oncology, and research and development; in October 2026, the Claude Science research workbench pilot was also launched, collaborating to refine data leak audit hooks. This cooperation greatly accelerated early target literature retrieval and research collaboration, but new drug approval generally takes more than 3 to 5 years from project initiation, and in the short term, large pharmaceutical companies' stock prices remain highly dependent on the rhythm of major drug releases and healthcare policies.

Another large pharmaceutical firm, Bristol Myers Squibb (BMY), is making even bigger strides. Previously, BMY executive Greg Meyers introduced their ability to compress the analysis of real-world evidence (RWE) that initially took one to two months down to 4 to 5 minutes, and they expect AI to reduce overall clinical trial time by 20% to 30%. Of course, influenced by factors such as patient recruitment speed, hospital ethical review, and FDA verification, the current 20% to 30% reduction remains within the company’s expectations and has not yet been realized in a full Phase III large-sample pipeline.

The leading clinical trial outsourcing firm IQVIA (IQV) is not to be overlooked. The company previously claimed that thanks to tools like AI large models, it achieved a 33% speedup in research initiation, a 50% speedup in data cleaning, and shortened trial phase intervals by more than 45% — allowing pharmaceutical companies to potentially launch new drugs to market up to 2 years earlier. Subsequently, with proprietary clinical databases, compliance experience, and around 94,000 employees, IQVIA could further achieve rapid growth if it upgrades its data platform and high-value agency services.

In national defense security, Palantir Technologies (PLTR) is a key player involved. Previously, Palantir CTO Shyam Sankar publicly emphasized that the US Pentagon has replaced Claude with xAI, OpenAI, Google, and Nvidia’s open-source model Nemotron in its Maven intelligent system without impacting its mission; in subsequent interviews, he also stressed that they would enhance customers’ ability to safely switch between different AI models. At present, it is not that PLTR needs Anthropic, but rather that Anthropic needs to handle its relationship with PLTR and the US Department of Defense.

Of course, if Anthropic expands to directly deliver end-to-end AI agents to federal and subordinate agencies, PLTR will also be impacted to a certain extent, but its stock price trend will still mainly depend on US national defense security spending and market sentiment in the AI sector.

179516772642526.jpg

Lastly, let’s talk about the targets related to computing power chips.

After subtly participating in the controversy surrounding Nvidia founder Jensen Huang's departure, Anthropic claimed, “We achieved a model running on AMD chips in 3 days,” and the impressive performance of AMD's financial report prior also led to a temporary rise in its stock price within the semiconductor sector despite adversities.

Anthropic’s roadshow materials and facts list AMD GPUs alongside Amazon Trainium, Google TPU, and Nvidia GPUs as four core computing power architectures; however, according to AI Daily Radar’s verification against the prospectus, the 3-day achievement only covers the prompt processing of a single model, excluding the much more complex large-scale cluster training and is solely disclosed by Anthropic; to date, there has been no independent benchmarking from third parties.

Yesterday, the short-seller Hunterbrook Media released a report accusing AMD products of violating export control regulations, triggering a sharp decline in its stock price. In the short term, Anthropic’s IPO remains a positive for AMD, but subsequent order verification is still needed to confirm whether its stock price can gain long-term support.

Regardless, change has occurred, and the butterfly effect triggered by Anthropic’s IPO will continue to spread in the coming years. As for its future growth direction, whether it becomes “the Leviathan in the field of AI,” or “the sword bearer of the AI industry,” will depend on the future paths chosen by company executives, including Dario.

免责声明:本文章仅代表作者个人观点,不代表本平台的立场和观点。本文章仅供信息分享,不构成对任何人的任何投资建议。用户与作者之间的任何争议,与本平台无关。如网页中刊载的文章或图片涉及侵权,请提供相关的权利证明和身份证明发送邮件到[email protected],本平台相关工作人员将会进行核查。

Share To
APP

X

Telegram

Facebook

Reddit

CopyLink